More on ACAD
Data
Financials
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $19.80 |
|
|||
| Open | $20.04 | ||||
| 52 Wk High | $42.49 | ||||
| 52 Wk Low | $16.64 | ||||
| Day High | $20.28 | ||||
| Day Low | $19.86 | ||||
| P/E | N/A | ||||
| EPS | $-0.42 | ||||
| Volume | 246,676 | ||||
- UBS Downgrades Acadia Pharmaceuticals (ACAD) to Neutral
- Acadia Pharmaceuticals (ACAD) PT Lowered to $36 at RBC Capital
- RBC Capital on Acadia Pharmaceuticals (ACAD): 'shares remain fundamentally undervalued'
- Acadia Pharmaceuticals Announces Allowance of U.S. Patent Covering Weight-Banded Dosing of Trofinetide, extending U.S. patent protections to March 2041
- Acadia Pharmaceuticals (ACAD) PT Lowered to $33 at H.C. Wainwright
- Increasing unusual option volume: GENI ACAD BUG XEL LESL GFL AKAM NKTR BURL QFIN
- Acadia Pharmaceuticals (ACAD) PT Lowered to $35 at Needham
- Acadia Pharmaceuticals (ACAD) PT Lowered to $33 at Citizens on Ph2 Miss for Remlifanserin
- Form 8-K ACADIA PHARMACEUTICALS For: Sep 24
- Goldman Sachs Reiterates Sell Rating on Acadia Pharmaceuticals (ACAD)
Entities mentioned with ACAD
- FDA | View Related Stories »
- Earnings | View Related Stories »
- Twitter | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- Needham & Company | View Related Stories »
- Definitive Agreement | View Related Stories »
- Show More...
